CY1108498T1 - Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη - Google Patents

Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη

Info

Publication number
CY1108498T1
CY1108498T1 CY081101283T CY081101283T CY1108498T1 CY 1108498 T1 CY1108498 T1 CY 1108498T1 CY 081101283 T CY081101283 T CY 081101283T CY 081101283 T CY081101283 T CY 081101283T CY 1108498 T1 CY1108498 T1 CY 1108498T1
Authority
CY
Cyprus
Prior art keywords
composition containing
vaccine composition
pharmaceutical composition
additionally contains
phosphatidyl choline
Prior art date
Application number
CY081101283T
Other languages
English (en)
Inventor
Jean Haensler
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of CY1108498T1 publication Critical patent/CY1108498T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια φαρμακευτική σύνθεση η οποία περιέχει ένα τουλάχιστον αντιγόνο εμβολίου, η οποία χαρακτηρίζεται από το ότι περιέχει επιπλέον ένα τουλάχιστον παράγωγο φωσφορικού εστέρα της φωσφατιδυλοχολίνης που έχει τον συντακτικό τύπο (τύπο Ι) στον οποίο το R1 είναι κατώτερο αλκύλιο, τα R2 και R3 είναι ίδια ή διαφορετικά, και μπορούν το καθένα να αντιπροσωπεύει ευθείες αλυσίδες υδρογονανθράκων που έχουν 13 έως 21 άτομα άνθρακα.
CY081101283T 2003-11-17 2008-11-11 Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη CY1108498T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313406A FR2862306B1 (fr) 2003-11-17 2003-11-17 Composition vaccinale
EP04805451A EP1696954B1 (fr) 2003-11-17 2004-11-15 Composition vaccinale adjuvantée par une alkylphosphatidylcholine

Publications (1)

Publication Number Publication Date
CY1108498T1 true CY1108498T1 (el) 2014-04-09

Family

ID=34508504

Family Applications (1)

Application Number Title Priority Date Filing Date
CY081101283T CY1108498T1 (el) 2003-11-17 2008-11-11 Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη

Country Status (23)

Country Link
US (2) US7344720B2 (el)
EP (1) EP1696954B1 (el)
JP (1) JP4638880B2 (el)
KR (1) KR101136107B1 (el)
CN (1) CN1882358B (el)
AT (1) ATE412429T1 (el)
AU (1) AU2004290943B2 (el)
BR (1) BRPI0416670A (el)
CA (1) CA2545086C (el)
CY (1) CY1108498T1 (el)
DE (1) DE602004017504D1 (el)
DK (1) DK1696954T3 (el)
ES (1) ES2311875T3 (el)
FR (1) FR2862306B1 (el)
IL (1) IL175573A (el)
LT (1) LT5435B (el)
LV (1) LV13457B (el)
NO (1) NO20062779L (el)
PL (1) PL1696954T3 (el)
PT (1) PT1696954E (el)
SI (1) SI1696954T1 (el)
WO (1) WO2005049080A1 (el)
ZA (1) ZA200603522B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100752990B1 (ko) * 2006-08-02 2007-08-30 주식회사 대웅 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
TWI444384B (zh) * 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
NZ597007A (en) 2009-05-14 2013-09-27 Sanofi Pasteur Meningococcus vaccine containing lipooligosaccharide (los) from modified strains of l6 immunotype neisseria meningitidis
AU2010247253A1 (en) * 2009-05-14 2012-01-12 Sanofi Pasteur Method for detoxification of lipopolysaccharide (LPS) or of lipid a of gram-negative bacteria
AU2010247252A1 (en) 2009-05-14 2012-01-12 Sanofi Pasteur Method for admixing the lipopolysaccharide (LPS) of gram-negative bacteria
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
JP5761143B2 (ja) * 2011-11-02 2015-08-12 株式会社リコー 撮像ユニット、撮像ユニットを搭載した車両
US20140147475A1 (en) * 2012-11-29 2014-05-29 Antonius Arnoldus Christiaan Jacobs Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
WO2014147001A1 (en) 2013-03-18 2014-09-25 Intervet International B.V. Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica
CA2955562C (en) 2014-07-21 2018-05-22 Thomas Gebhard Liquid feeding device for the generation of droplets

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
CN1468089B (zh) 2000-09-28 2011-09-21 诺华疫苗和诊断公司 用于传送异源核酸的微粒体
JP4164361B2 (ja) * 2000-11-07 2008-10-15 イムノワクチン テクノロジーズ インコーポレーテッド 増強した免疫応答を有するワクチン、およびその調製方法
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use

Also Published As

Publication number Publication date
IL175573A0 (en) 2006-09-05
FR2862306B1 (fr) 2008-05-30
AU2004290943A1 (en) 2005-06-02
WO2005049080B1 (fr) 2005-09-01
JP2007511585A (ja) 2007-05-10
CN1882358A (zh) 2006-12-20
IL175573A (en) 2010-06-30
LT5435B (lt) 2007-07-25
CN1882358B (zh) 2011-02-02
EP1696954A1 (fr) 2006-09-06
KR20060127385A (ko) 2006-12-12
FR2862306A1 (fr) 2005-05-20
DK1696954T3 (da) 2009-02-23
SI1696954T1 (sl) 2009-04-30
JP4638880B2 (ja) 2011-02-23
CA2545086C (en) 2011-11-08
KR101136107B1 (ko) 2012-04-17
AU2004290943B2 (en) 2009-08-27
DE602004017504D1 (de) 2008-12-11
EP1696954B1 (fr) 2008-10-29
CA2545086A1 (en) 2005-06-02
ZA200603522B (en) 2007-07-25
BRPI0416670A (pt) 2007-02-13
NO20062779L (no) 2006-08-15
WO2005049080A1 (fr) 2005-06-02
US20050208060A1 (en) 2005-09-22
LV13457B (en) 2007-01-20
PL1696954T3 (pl) 2009-04-30
ATE412429T1 (de) 2008-11-15
ES2311875T3 (es) 2009-02-16
LT2006036A (en) 2007-05-25
US7344720B2 (en) 2008-03-18
US7767658B2 (en) 2010-08-03
US20080131446A1 (en) 2008-06-05
PT1696954E (pt) 2008-11-25

Similar Documents

Publication Publication Date Title
CY1108498T1 (el) Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
BR0010555A (pt) Inibidores de neuraminidases
EA200501098A1 (ru) Антибактериальные агенты
CY1108295T1 (el) Παραγωγα μονοσακχαριτη αβερμεκτινης τα οποια εχουν παρασιτοκτονες ιδιοτητες
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
RU2009106934A (ru) Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1110694T1 (el) Μεθοδος παρασκευης παραγωγων της εχινοκανδινης
ATE299871T1 (de) Neue zyklische depsipeptid pf1022 derivate
ES2186550B2 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
ECSP045396A (es) Proceso para preparar derivados de 6-alquiliden penem
ES2169242T3 (es) 2-amino-benzoxazinonas para el tratamiento de infecciones virales.
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
ES2162916T3 (es) Derivados de acido pirimidin- o triazincarboxilico para el empleo como medicamentos.
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
RU2009111262A (ru) Лечение микобактериальных инфекций циклипостинами
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
SE0002739D0 (sv) New use
PT1280812E (pt) Ciclipostinas, processo para a sua preparacao e sua utilizacao
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции